Elevance Health (ELV) faced a significant setback with a substantial cut to its 2025 adjusted EPS forecast from a range of $34.15 – $34.85 to $30.00. This revision followed disappointing quarterly results where the company reported adjusted EPS down 13% year-over-year and sales at $49.4 billion, a 14% increase from the previous year. Analysts have responded negatively, assigning a Zacks Rank #5 (Strong Sell) to the stock.
These challenges are attributed to ongoing cost pressures in the ACA and Medicaid sectors, leading to concerns about the company’s earnings outlook. Following the earnings report, Elevance Health’s shares experienced a notable decline, reflecting investor sentiment regarding the revised guidance.
